H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on ObsEva SA (NASDAQ: OBSV) today and set a price target of $28. The company’s shares closed on Friday at $12.89.
Selvaraju commented:
“We note that the Phase 2b EDELWEISS trial of OBE2109 in endometriosis patients—which has completed enrollment of 330 subjects—could position OBE2109 as the only GnRH receptor antagonist with the possibility of use without add-back therapy (ABT), which is slated to be required for both elagolix and relugolix (the other agents in this drug class). In our view, the potential for OBE2109 to be used both with and without ABT should provide it with best-in-class status, since the drug would thus have substantial convenience and safety advantages for patients. Positive data in EDELWEISS should pave the way for pivotal entry in endometriosis for OBE2109, with two randomized, placebo-controlled, double-blinded clinical studies designed to 1,000 subjects combined likely to form the basis of the Phase 3 program.”
According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -2.8% and a 39.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
ObsEva SA has an analyst consensus of Strong Buy, with a price target consensus of $22.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.81 and a one-year low of $5. Currently, ObsEva SA has an average volume of 41.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ObsEva SA engages in the development of therapeutic treatments for woman’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet in November 2012 and is headquartered in Geneva, Switzerland.
